# US 2002/0058336 A1 · Adhesion modulatory peptides and methods for use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058336 A1
- Document ID: US20020058336A1
- Status: Published application
- Kind: A1
- Application number: 09/732,411
- Filed: 2000-12-07
- Published: 2002-05-16
- Earliest claimed: 1999-04-16
- Inventors: Samy Ashkar
- Web page: https://patentgrep.com/patent/US20020058336A1

## CPC

- C07K 14/70546: {Integrin superfamily}
- A61P 9/14: Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 35/04: specific for metastasis
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods for modulating cell adhesion. The invention also provides novel adhesion modulatory peptides, substrates coated with such adhesion modulatory peptides and devices for modulation of target cell adhesion.

## Claims

### Claim 1

A method of modulating adhesion of a target cell to a substrate, comprising providing the target cell with an adhesion modulatory peptide-associated substrate such that adhesion of the target cell to the substrate is modulated.

### Claim 2 (depends on 1)

The method of claim 1, wherein the adhesion modulatory peptide comprises a peptide which specifically enhances adhesion of the target cell.

### Claim 3 (depends on 1)

The method of claim 1, wherein the adhesion modulatory peptide comprises a peptide which specifically inhibits adhesion of the target cell

### Claim 4 (depends on 1)

The method of claim 1, wherein the adhesion modulatory peptide is selected from the group consisting of an endothelial cell adhesion modulatory peptide, a fibroblast adhesion modulatory peptide and a macrophage adhesion modulatory peptide.

### Claim 5 (depends on 4)

The method of claim 4, wherein the adhesion modulatory peptide is an endothelial cell adhesion modulatory peptide.

### Claim 6 (depends on 4)

The method of claim 4, wherein the adhesion modulatory peptide is a fibroblast adhesion modulatory peptide.

### Claim 7 (depends on 4)

The method of claim 4, wherein the adhesion modulatory peptide is a neotrophil adhesion modulatory peptide or a myofibroblast adhesion modulatory peptide.

### Claim 8 (depends on 1)

The method of claim 1, wherein the adhesion modulatory peptide comprises an amino acid residue sequence selected from the group consisting of SDQDNNGKGSHES (SEQ ID NO:1), SDQDQDGDGHQDS (SEQ ID NO:2), GRGDNPS (SEQ ID NO:3), TPVVPTVDTYDGRGDSLAY (SEQ ID NO:4), TPVVPTVDTYDGRGD (SEQ ID NO:5), HDRKEFAKFEEERARA (SEQ ID NO:10), DPGYIGSR (SEQ ID NO:10), KGMNYTVR (SEQ ID NO:13), and VLEP (SEQ ID NO:15).

### Claim 9 (depends on 1)

The method of claim 1, wherein the adhesion modulatory peptide comprises an amino acid residue sequence selected from the group consisting of DDDRKWGFC (SEQ ID NO:6), DSVVYGLRSK (SEQ ID NO:7), LDSAS (SEQ ID NO:8), SDV (SEQ ID NO:9), PNGRGESLAY (SEQ ID NO:11), and DRYLKFRPV (SEQ ID NO:12).

### Claim 10 (depends on 1)

The method of claim 1, wherein the adhesion modulatory molecule enhances binding of an adhesion receptor predominantly expressed by the target cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein the adhesion modulatory molecule inhibits binding of an adhesion receptor predominantly expressed by the target cell.

### Claim 12 (depends on 1)

The method of claim 1, wherein the target cell is selected from the group consisting of an endothelial cell, a fibroblast and a macrophage.

### Claim 13 (depends on 12)

The method of claim 12, wherein the target cell is an endothelial cell.

### Claim 14 (depends on 12)

The method of claim 12, wherein the target cell is a fibroblast.

### Claim 15 (depends on 1)

The method of claim 1, wherein the target cell is a neutrophil or a myofiboblast.

### Claim 16 (depends on 1)

The method of claim 1, wherein the target cell is within a cell population.

### Claim 17 (depends on 1)

The method of claim 1, wherein the target cell is within a subject.

### Claim 18 (depends on 1)

The method of claim 1, wherein the substrate is selected from the group consisting of a polyvinyl surface, a gel, collagen, hyaluronic acid, titanium and PGA.

### Claim 19 (depends on 1)

The method of claim 1, further comprising contacting the substrate with the adhesion modulatory peptide, forming the adhesion modulatory peptide-associated substrate prior to providing the cell with the substrate.

### Claim 20

An adhesion modulatory peptide which modulates adhesion of a target cell to a substrate.

### Claim 21 (depends on 20)

The adhesion modulatory peptide of claim 20, wherein the peptide enhances adhesion of a target cell to a substrate.

### Claim 22 (depends on 20)

The adhesion modulatory peptide of claim 20, wherein the peptide inhibits adhesion of a target cell to a substrate.

### Claim 23 (depends on 20)

The adhesion modulatory peptide of claim 20, comprising an amino acid residue sequence selected from the group consisting of SDQDNNGKGSHES (SEQ ID NO:1), SDQDQDGDGHQDS (SEQ ID NO:2), GRGDNPS (SEQ ID NO:3), TPVVPTVDTYDGRGDSLAY (SEQ ID NO:4), TPVVPTVDTYDGRGD (SEQ ID NO:5), HDRKEFAKFEEERARA (SEQ ID NO:9), DPGYIGSR (SEQ ID NO:10), KGMNYTVR (SEQ ID NO:13) and VLEP (SEQ ID NO:15).

### Claim 24 (depends on 20)

The adhesion modulatory peptide of claim 20, comprising an amino acid residue sequence selected from the group consisting of DDDRKWGFC (SEQ ID NO:6), DSVVYGLRSK (SEQ ID NO:7), LDSAS (SEQ ID NO:8), SDV (SEQ ID NO:9), PNGRGESLAY (SEQ ID NO:12), and DRYLKFRPV (SEQ ID NO:13).

### Claim 25 (depends on 20)

The adhesion modulatory peptide of claim 20 having a molecular weight less than about 2500 Da.

### Claim 26 (depends on 20)

A substrate treated with the adhesion modulatory peptide of claim 20.

### Claim 27 (depends on 20)

A device treated with the adhesion modulatory peptide of claim 20.

### Claim 28 (depends on 20)

A composition comprising the adhesion modulatory peptide of claim 20 and a carrier suitable for in vivo use.

### Claim 29

A device for modulation of adhesion of a target cell comprising a substrate in combination with an adhesion-modulatory peptide, forming a device for modulating adhesion.
